Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pisa – page 43

582 clinical trials in Pisa, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pisa at a glance
582
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

582 trials in Pisa

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study on Retreatment with Encorafenib and Cetuximab for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondazione GONO G.I.

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Fungal infection

Not recruiting

Study on the Effectiveness and Safety of Olorofim vs. Liposomal Amphotericin B for Patients with Invasive Aspergillosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olorofim
  • Sponsor:F2G Limited

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Linsitinib
  • Sponsor:Sling Therapeutics Inc.

General anaesthesia

Not recruiting

Study on the Effects of Low-Dose Sevoflurane, Dexmedetomidine, and Remifentanil Anesthesia on Neurodevelopment in Children Under 2 Undergoing Long Surgeries

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Sevoflurane
  • Sponsor:IRCCS Istituto Giannina Gaslini

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pisa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Investigating innovative treatments for cardiac conditions and metabolic disorders, with studies focusing on TTR amyloidosis cardiomyopathy and chronic kidney disease management.

  • Heart Disease Therapeutics
  • Kidney Disease Management
  • Hypertension Control

Current trials evaluate novel compounds for improving patient outcomes in cardiac conditions and renal disorders.

02 Oncology Studies

Comprehensive research into various cancer types, including colorectal cancer, gastric cancer, and lung cancer, testing targeted therapies and innovative treatment combinations.

  • Metastatic Cancer Treatment
  • Targeted Therapy Development
  • Immunotherapy Research

Advanced clinical trials exploring breakthrough treatments for multiple cancer types.

03 Autoimmune & Inflammatory Conditions

Studies focusing on chronic inflammatory conditions including Sjögren's Syndrome, psoriatic arthritis, and hidradenitis suppurativa.

  • Inflammatory Disease Management
  • Autoimmune Treatment Innovation
  • Novel Therapeutic Approaches

Evaluating new therapeutic options for improving quality of life in patients with chronic inflammatory conditions.

04 Respiratory & Infectious Diseases

Research into respiratory conditions and infectious diseases, including studies on chronic rhinosinusitis and respiratory syncytial virus infections.

  • Respiratory Disease Treatment
  • Infection Management
  • Vaccine Development

Investigating new approaches to treat and prevent respiratory infections and related conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.